Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LKB1 orchestrates dendritic cell metabolic quiescence and anti-tumor immunity

ABSTRACT: LKB1 orchestrates dendritic cell metabolic quiescence and anti-tumor immunity

PROVIDER: PRJNA527815 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

LKB1 orchestrates dendritic cell metabolic quiescence and anti-tumor immunity [HT_MG-430_PM]

Project description:LKB1 orchestrates dendritic cell metabolic quiescence and anti-tumor immunity [HT_MG-430_PM]

| PRJNA527819 | ENA

LKB1 orchestrates dendritic cell metabolic quiescence and anti-tumor immunity [MoGene-2_0-st]

Project description:LKB1 orchestrates dendritic cell metabolic quiescence and anti-tumor immunity [MoGene-2_0-st]

| PRJNA527817 | ENA

LKB1 orchestrates dendritic cell metabolic quiescence and anti-tumor immunity.

Project description: Not available

| S-EPMC6796952 | biostudies-literature

LKB1 orchestrates dendritic cell metabolic quiescence and anti-tumor immunity [HT_MG-430_PM]

Project description:Loss of LKB1 leads to aberrant DC maturation and production of cytokines and immunoregulatory molecules. DCs (n = 7 per genotype) were isolated from the spleen, and CD25+CD4+ Tregs (n = 4 for WT, n = 3 for LKB1ΔDC mice) were isolated from the spleen and peripheral lymph nodes of WT and LKB1ΔDC mice.

2019-04-16 | GSE128474 | GEO

LKB1 orchestrates dendritic cell metabolic quiescence and anti-tumor immunity [MoGene-2_0-st]

2019-04-16 | GSE128473 | GEO

LKB1 orchestrates dendritic cell metabolic quiescence and anti-tumor immunity

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-04-16 | GSE128475 | GEO

LKB1 prevents ILC2 exhaustion and lung cancer metastasis

Project description:Group 2 innate lymphoid cells (ILC2s) mediate type 2 immune responses involved in anti-helminth immunity, allergic inflammation, and metabolic homeostasis. Recently, they have emerged as key players in regulating tumor immunity. The tumor suppressor liver kinase B1 (LKB1) inactivating mutations is associated with a variety of human cancers, but the role of LKB1 in ILC2 function and ILC2-mediated tumor immunity remains unknown. Here, we show that LKB1 is required for mature ILC2 survival. Ablation of LKB1 in ILC2s results in impaired proliferation and a marked decrease in type 2 cytokine production upon activation, accompanied with the expression of exhaustion signature genes and reduced cellular metabolism, which promote the development of lung melanoma metastasis. In addition, LKB1 deficiency leads to a marked increase of programmed cell death protein-1 (PD-1) expression in ILC2s through activation of nuclear factor of activated T cells (NFAT) pathway. Blockade of PD-1 can restore type 2 cytokine production in LKB1-deficient ILC2 and reverse its exhaustion state, leading to enhanced antitumor immune responses in vivo. Together, our results reveal that LKB1 retrains ILC2 exhaustion state to maintain immune homeostasis and their antitumor immunity.

2024-05-21 | GSE209588 | GEO

CDK4/6 inhibitors reverse primary resistance to anti-PD-1 therapy in LKB1-deficient lung adenocarcinoma

Project description:LKB1 deficiency in lung adenocarcinoma (LUAD) leads to primary resistance to immune checkpoint inhibitors. However, the underlying molecular mechanism remains unclear. Here, we showed that LKB1 deficiency significantly affected the tumor immune landscape by decreasing the infiltration of most immunocyte populations and downregulating the expression of intercellular adhesion molecule-1 (ICAM1). LKB1 deficiency promoted cancer evasion due to loss of ICAM1-mediated antitumor immunity, including immune-competent cell cytotoxicity and tumor infiltration. CDK4/6 inhibitors reversed this process in a targeted manner. A tailored combination strategy using CDK4/6 inhibitors and anti-PD-1 antibodies slowed tumor growth and increased survival in syngeneic mouse models of LKB1-deficient lung adenocarcinoma. Combining a CDK4/6 inhibitor, which is clinically approved, with PD-1 blockade therapy is thus a promising option for lung adenocarcinoma patients harboring LKB1 mutations.

2022-12-16 | GSE182228 | GEO

Transcription profiling of Mus musculus gastric Lkb1 polyps vs unaffected gastric Lkb1 mucosa

Project description:Gene expression in wildtype mouse stomach wall (n=6), Lkb1+/- mouse stomach wall (n=6) and Lkb1+/- mouse gastric polyps

2010-10-06 | E-MEXP-2444 | biostudies-arrayexpress

Enteric Nervous System Derived IL-18 Orchestrates Mucosal Barrier Immunity

Project description:Enteric Nervous System Derived IL-18 Orchestrates Mucosal Barrier Immunity

| PRJNA594857 | ENA